Volume 10, Number 11—November 2004
Research
Histopathologic Improvement with Lymphedema Management, Léogâne, Haiti
Susan F. Wilson*, Jeannette Guarner*, Alix L. Valme†, Jacky Louis-Charles†, Tara L. Jones*, and David G. Addiss*
Table 3
Number and percentage of skin biopsy specimens in which histopathologic features were detected in 27 patients practicing lymphedema management, Léogâne, Haitia
| Location in skin | Histopathologic characteristic | 1st biopsy (N = 27) n (%) | 2nd biopsy (N = 27) n (%) | p value |
|---|---|---|---|---|
| Epidermis | Hyperkeratosis | 14 (52) | 12 (44) | 0.59 |
| Hypergranulosis | 5 (18) | 1 (4) | 0.09 | |
| Acanthosis | 7 (26) | 3 (11) | 0.16 | |
| Superficial dermis | Fibrolamellar hyperplasia | 16 (59) | 11 (41) | 0.18 |
| Condensed collagen | 10 (37) | 5 (18) | 0.13 | |
| Perivascular fibrosis | 4 (15) | 1 (4) | 0.17 | |
| Perivascular infiltrate | ||||
| Acute | 0 (0) | 0 (0) | ||
| Chronic | 27 (100) | 16 (59) | 0.0002 | |
| Pronounced intensity | 10 (37) | 3 (11) | 0.03 | |
| Presence of plasma cells | 7 (26) | 4 (15) | 0.31 | |
| Deep dermis | Perivascular fibrosis | 14 (52) | 6 (22) | 0.02 |
| Perivascular infiltrate | ||||
| Acute | 0 (0) | 0 (0) | ||
| Chronic | 25 (93) | 21 (78) | 0.12 | |
| Pronounced intensity | 9 (33) | 6 (22) | 0.37 | |
| Presence of plasma cells | 18 (67) | 18 (67) | 1 | |
| Periadnexal infiltrate | ||||
| Acute | 0 (0) | 0 (0) | ||
| Chronic | 19 (70) | 9 (33) | 0.007 | |
| Pronounced intensity | 7 (26) | 0 (0) | 0.005 | |
| Subcutaneous tissue | Infiltrate in fibrous septa | |||
| Acute | 0 (0) | 0 (0) | ||
| Chronic | 10 (37) | 10 (37) | 1 | |
| Pronounced intensity | 5 (18) | 1 (4) | 0.09 |
aFor each patient, the second biopsy specimen was taken near the same site on the same lymphedematous leg ≈1 year after the first biopsy.
Page created: April 22, 2011
Page updated: April 22, 2011
Page reviewed: April 22, 2011
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.